on ITolerance, Inc.
University of Miami Announces Breakthrough in Diabetes Treatment at ADA 2024
The Diabetes Research Institute (DRI) at the University of Miami has unveiled promising results in Type 1 Diabetes treatment at the American Diabetes Association's 84th Scientific Sessions. This advancement involves a blend of human stem cell-derived islets and an immunomodulatory microgel. This approach may reverse Type 1 Diabetes without chronic systemic immunosuppression.
The effort, led by Dr. Giacomo Lanzoni at the DRI, demonstrates that this combination can restore normoglycemia in diabetes models. The collaboration includes iTolerance, Inc. and Kadimastem, Ltd, highlighting the iTOL-100 microgel and IsletRx stem cell-derived islets.
Dr. Lanzoni and Dr. Camillo Ricordi from DRI emphasized the transformative potential of this method for scalable and safe islet cell transplantation. The study shows that combining these technologies preserves the functionality of the transplanted islets.
Dr. Anthony Japour of iTolerance and Prof. Michel Revel of Kadimastem praised the joint work. The innovation allows islet cell transplantation without full immunosuppression, a critical step towards practical and widespread diabetes treatment solutions.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ITolerance, Inc. news